Suzuki, Fumitaka
Hatanaka, Naoya
Bando, Etsuya
Nakamura, Koji
Komoto, Akira
Funding for this research was provided by:
Bristol-Myers Squibb K.K., Japan
Article History
Received: 19 February 2018
Accepted: 16 May 2018
First Online: 9 June 2018
Compliance with ethical standards
:
: Fumitaka Suzuki has received personal fees from Abbott Japan, AbbVie, ASKA Pharmaceutical, BMS K.K., Chugai Pharmaceutical, Gilead Sciences, GlaxoSmithKline, Mitsubishi Tanabe Pharma Corporation, MSD, Otsuka Pharmaceutical, Roche Diagnostics, and Sumitomo Dainippon Pharma. Naoya Hatanaka, Etsuya Bando, Koji Nakamura, and Akira Komoto are employees of BMS K.K.
: This postmarketing surveillance (PMS) was conducted in accordance with Good Postmarketing Surveillance Practices (GPSP) as per the Japanese Pharmaceutical Affairs Law. Under GPSP regulations, Institutional Review Board approval and written informed consent are not required. This PMS is registered at ClinicalTrials.gov (NCT02250001).
Free to read: This content has been made available to all.